Endometrial serous adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A high grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Endometrial serous adenocarcinoma
- Therapeutic area
- Oncology
- endometrial serous adenocarcinoma
- uterine serous adenocarcinoma
- uterine serous carcinoma
- body of uterus serous adenocarcinoma
- endometrial serous adenocarcinoma
- serous endometrial adenocarcinoma
- uterine corpus serous adenocarcinoma
- uterine papillary serous carcinoma
- uterine serous papillary adenocarcinoma
- uterine serous carcinoma/uterine papillary serous carcinoma
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0006196
- Parent condition
- MONDO:0005213
Related records
Broader conditions (25)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Corpus uteri neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Glandular cell neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
- Serous adenocarcinoma
Trials (51)
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
- AMT-151 in Patients With Selected Advanced Solid Tumours
- Azenosertib in Uterine Serous Carcinoma: Biomarker Study
- Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
- Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
- Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
- Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
- Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Drugs in development (2)
- Adavosertib Phase 2
- Azenosertib Phase 2
Other linked drugs (1)
- Triapine